Should we reconsider our therapeutic goals in 2011 pr bernard charbonnel nantes
This presentation is the property of its rightful owner.
Sponsored Links
1 / 18

«  Should we reconsider our therapeutic goals in 2011 ? » Pr. Bernard CHARBONNEL - Nantes PowerPoint PPT Presentation


  • 64 Views
  • Uploaded on
  • Presentation posted in: General

«  Should we reconsider our therapeutic goals in 2011 ? » Pr. Bernard CHARBONNEL - Nantes . SFD Congress -Geneva Reported by Dr Ramona Abi Gerges. Publications :. N Engl J Med 2011; 364:818-28 N Engl J Med 2003; 348:383-93 N Engl J Med 2011 ;364:829-41

Download Presentation

«  Should we reconsider our therapeutic goals in 2011 ? » Pr. Bernard CHARBONNEL - Nantes

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Should we reconsider our therapeutic goals in 2011 pr bernard charbonnel nantes

« Shouldwereconsiderourtherapeutic goals in 2011 ? » Pr. Bernard CHARBONNEL - Nantes

SFD Congress-Geneva

Reported by

Dr Ramona AbiGerges


Publications

Publications :

  • N Engl J Med 2011;364:818-28

  • N Engl J Med 2003;348:383-93

  • N Engl J Med 2011;364:829-41

  • The Lancet 2010, vol.375,issue 9713, Pages 481 - 489

  • Diabetes Care 2010,April 28 vol. 33 no. 5 983-990

  • Diabetologia 2010, 53:2079–2085

  • Diabetologia 2009,52:2288–2298

  • BMJ 2010; 340:b5444

  • BMJ 2000; 321:405-12

  • Annals of Internal Medicine 2009, Vol.151 • Nbr 6-396


Should we reconsider our therapeutic goals in 2011 pr bernard charbonnel nantes

  • No epidemiologic argument in favor of poor glycemic control

  • Paradoxical results in ACCORD showed that mortality increases when

    HBA1C<6% and >8%

  • UKPDS: reduction in micro-vascular , microalbuminuria complications when HBA1C<8%


Should we reconsider our therapeutic goals in 2011 pr bernard charbonnel nantes

  • Reasonsfor increased mortality

  • Rapiddecrease in HBA1c ?

  • Severehypoglycemia ?

  • Uncontrolledhyperglycemiaitself?

  • Drug interactions, polymedications?


Diabetes care doi 10 2337 dc09 1278

EpidemiologicRelationshipsBetween A1C and All-Cause MortalityDuring a Median 3.4-YearFollow-up of GlycemicTreatment in the ACCORD Trial

Diabetes Care doi: 10.2337/dc09-1278


Conclusion

Conclusion

  • Hba1c is a marker of risk of complication

  • Hypoglycemia is a marker of risk of mortality rather than reason

  • The objective of the treatment is not to bring down HBA1C but to prevent complications micro and macro-vascular, irreversible once installed


Conclusion1

Conclusion

  • The target HbA1c varies between 6,5 % and 8 % according to the patients

  • The individualization of the therapeutic way remains the best daily approach in our clinical practice

  • « Earlier?Probably» « More extremely?Probably not »


Thank you

Thank you


  • Login